Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 5—May 2006
THEME ISSUE
Tuberculosis Special Section

Research

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom

I-Ching Sam*1, Francis Drobniewski*Comments to Author , Philip More*, Melanie Kemp*, and Timothy Brown*
Author affiliations: *Health Protection Agency, London, United Kingdom

Main Article

Table 7

Sequence analysis of 10 discrepant rifampin-susceptibility results*

Sample no. Rifampin susceptibility
LiPA result Phenotypic result Conclusion after sequencing
1–3 Sensitive Resistant From the same patient; wild-type rpoB test region
4 Sensitive Resistant Mycobacterium bovis; wild-type rpoB test region
5–7 Resistant (DS4) Sensitive From the same patient; synonymous substitution (R528R) not associated with rifampin resistance
8 Resistant (DS1) Sensitive 2 genotypes present: wild-type (predominant) and mutant (L511P)
9 Resistant (R5) Sensitive S531L mutation; wild-type rpoB on retesting, thus likely laboratory error
10 Resistant (DS2) Sensitive D516A mutation; no high-level resistance when seen alone

*LiPA, line probe assay.

Main Article

1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO